Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other so…
Screened 2026-08-27 · the tape above runs as of 10:31 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markup label.
Iovance Biotherapeutics, Inc. holds its Markup at $8.26. Consolidating, no directional conviction, held for 17 days.
As held on the ledger · 2026-08-27
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 17 days
Price at the screen
$8.26
Valuation
N/A trailing · -28.75 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.70
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
5.41%
Below 33%
Interest-bearing debt is just 5.4% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
14.66%
Below 33%
Cash held in interest-bearing accounts and securities is 14.7% of assets, under the one-third limit.
Pass
Receivables
26.89%
Below 49%
Money owed to the company is 26.9% of assets, under the 49% limit.
Pass
Revenue purity
3.91%
Below 5%
Only 3.9% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-08-27 screen. The gold marker is the market price at the same screen. A 21.1% margin of safety to the base estimate.
Third-party analyst targets: 9 covering, consensus Buy. The average target sits +21% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-08-27 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Cell therapy hopes hit a wall of losses
When a patient waits for a last-line melanoma treatment, the promise of harvesting their own immune cells feels like genuine progress. Iovance is trying to turn that science into a repeatable commercial product across solid tumours.
Revenue is climbing at 45 percent, analysts see a path to roughly ten dollars, and the ethical screen is clear. Yet forward earnings sit at minus 15.7 times, profit margins are minus 124 percent, and return on equity is minus 48 percent. No identifiable moat and our opportunity rating is none.
The sector is littered with companies that grew fast then burned cash until dilution or failure arrived. Negative profitability at this scale leaves little room for execution slips or delayed approvals. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
IOVA trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-09-02Markup$8.26+65.2%Entry 5
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 65.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 51% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 58%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (10 analysts) rates it buy, with a mean price target of $9.
2026-08-02Markup$5.00+22.5%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 22.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 51% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 58%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (10 analysts) rates it buy, with a mean price target of $9.
2026-07-18Markup$4.08+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 51% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 58%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (10 analysts) rates it buy, with a mean price target of $9.
2026-07-03Markup$4.08+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Markup$4.08Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
